Mnemosyne closes on additional $6M in Series A funding

Mnemosyne Pharmaceuticals Inc. closed today on an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders. More

To continue reading this article, please do one of the following.



biotechnology

Mnemosyne closes on additional $6M in Series A funding

COURTESY MNEMOSYNE PHARMACEUTICALS INC.
MNEMOSYNE PHARMACEUTICALS INC. closed on an additional $6 million in a Series A financing round, bringing its total Series A funding up to $11.4 million.
Posted 6/21/13

PROVIDENCE – Mnemosyne Pharmaceuticals Inc. closed today on an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders.

The new financing is from Atlas Venture, a Cambridge, Mass., early stage investment firm dedicated to financing disruptive innovation in life sciences and technology, and from Clal Biotechnology Industries, an Israeli firm, according to Kollol Pal, president and CEO of Mnemosyne.

The new funding brings the total of Series A financing raised to $11.4 million, combined with an earlier $5.4 million in Series A financing in 2012, led by Access BridgeGap Ventures, which included support from its existing investor, the Slater Technology Fund.

Slater has invested a total of $1 million in the firm.

Pal, who has described his startup as “the poster child” for the emerging Knowledge District because of its pairing of science and entrepreneurship, called the new investment “from a top tier fund very exciting.”

Pal said that while clinical trials are “still far away,” the new financing from Atlas and Clal is a strong endorsement of Mnemosyne’s science and entrepreneurial leadership.

Pal told Providence Business News that the company was also in discussion with potential pharmaceutical partners on a different drug development effort “that will be another magnitude of potential investment.”

Calendar
PBN Hosted
Events

Estate and Corporate Income Taxes are changing next year, and business owners and executives should know the details. The PBN Summit on November 6th will provide those details and more - including how much Obamacare's Employer Mandate could cost.
Advertisement
Purchase Data
Book of Lists
Lists
Book of Lists cover
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.
Data icons
Data can be purchased as single lists, in either Excel or PDF format; the entire database of the published book, in Excel format; or a printed copy of the Book of Lists.
  • Purchase an e-File of a single list
  •  
  • Purchase an e-File of the entire Book of Lists database
  •  
  • Purchase a printed copy of the Book of Lists
  •  
    National
    Local
    Latest News
    Advertisement